Sarcomas are rare mesenchymally derived tumors for which there are limited treatment options. This paper discusses the current therapeutic potential of directed tyrosine kinase inhibitors (TKIs) in sarcoma.
Methods
The authors review antibody-based strategies and small molecular inhibitors of TKIs, with specific emphasis placed on the potential use of these targeted agents as therapeutic options for the treatment of sarcomas that are not gastrointestinal stromal tumors.
Results
Many TKs have been shown to be mutated or overexpressed in human sarcoma tumors and cell lines and may serve as potential targets for promising new sarcoma therapies. Furthermore, the novel mechanism of targeting TKs may complement the antitumor activity of existing sarcoma treatment options.
Conclusions
TKIs such as imatinib, sunitinib, and sorefanib are promising new therapeutic options for the management of patients with soft tissue sarcoma.
AlbrittonK.H.. Sarcomas in adolescents and young adults.Hematol Oncol Clin North Am.2005; 19: 527–546, vii.
3.
BleyerW.A., MontelloM., BuddT.. National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation.Cancer.2005; 103: 1891–1897.
4.
BleyerW.A.. The adolescent gap in cancer treatment.J Regist Manage.1996; 23: 114–115.
5.
BleyerW.A., TejedaH., MurphyS.B.. National cancer clinical trials: children have equal access; adolescents do not.J Adolesc Health.1997; 21: 366–373.
6.
BleyerA., MontelloM., BuddT.. National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation.Cancer.2005; 103: 1891–1897.
7.
JemalA., TiwariR.C., MurrayT.. Cancer statistics, 2004.CA Cancer J Clin.2004; 54: 8–29.
8.
ChughR., ThomasD., WathenK.. Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial.J Clin Oncol.2004; 22 (14S July 15 suppl): 9001. Abstract.
9.
MorganJ.. Durable responses to SU11248 (sunitinib malate) are observed across all genotypes of imatinib mesylate-resistant GIST. Presented at the 17th International Congress on Anti-Cancer Treatment. January 2006; Paris, France.
10.
HelmanL.J., MeltzerP.. Mechanisms of sarcoma development.Nat Rev Cancer.2003; 3: 685–694.
11.
NicholsG.L.. Tyrosine kinase inhibitors as cancer therapy.Cancer Invest.2003; 21: 758–771.
12.
van OosteromA.T., JudsonI., VerweijJ.. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.Lancet.2001; 358: 1421–1423.
13.
McArthurG.A., DemetriG.D., van OosteromA.. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.J Clin Oncol.2005; 23: 866–873.
DeMatteoR.P., LewisJ.J., LeungD.. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.Ann Surg.2000; 231: 51–58.
16.
DuensingA., HeinrichM.C., FletcherC.D.. Biology of gastrointestinal stromal tumors: KIT mutations and beyond.Cancer Invest.2004; 22: 106–116.
17.
GossG., MerriamP., ManolaJ.. Clinical and pathological characteristics of gastrointestinal stromal tumors (GISTs).Proc Annu Meet Am Soc Clin Oncol.2000; 19: 2203. Abstract.
18.
HeinrichM., CorlessC., BlankeC.. KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs).Proc Annu Meet Am Soc Clin Oncol.2002; 21: 6. Abstract.
19.
JoensuuH., RobertsP.J., Sarlomo-RikalaM.. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.N Engl J Med.2001; 344: 1052–1056.
20.
SchindlerC.G., ArmbrustT., GunawanB.. Gastrointestinal stromal tumor (GIST): single center experience of prolonged treatment with imatinib.Z Gastroenterol.2005; 43: 267–273.
21.
VerweijJ., CasaliP.G., ZalcbergJ.. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.Lancet.2004; 364: 1127–1134.
22.
DemetriG.D., von MehrenM., BlankeC.D.. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med.2002; 347: 472–480.
RubinB.P., SingerS., TsaoC.. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.Cancer Res.2001; 61: 8118–8121.
25.
KoonH.B., BubleyG.J., PantanowitzL.. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.J Clin Oncol.2005; 23: 982–989. Epub 2004 Nov 30
26.
ScotlandiK., ManaraM.C., StrammielloR.. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.J Clin Oncol.2003; 21: 1952–1960.
27.
MerchantM.S., WooC.W., MackallC.L.. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.J Natl Cancer Inst.2002; 94: 1673–1679.
28.
DrukerB.J., TalpazM., RestaD.J.. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.N Engl J Med.2001; 344: 1031–1037.
29.
DrukerB.J., SawyersC.L., KantarjianH.. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.N Engl J Med.2001; 344: 1038–1042. Erratum in: N Engl J Med. 2001;345: 232.
30.
PengB., HayesM., Racine-PoonA.. Clinical investigation of the pharmacokinetic/pharmacodynamic relationship for Glivec (STI571): a novel inhibitor of signal transduction.Proc Annu Meet Am Soc Clin Oncol.2001; 20: 280a. Abstract.
31.
DrukerB.J.. Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work?J Natl Cancer Inst.2002; 94: 1660–1661.
32.
YoshitaniK., HonokiK., MorishitaT.. Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571.In Vivo.2003; 17: 255–258.
33.
McGaryE.C., WeberK., MillsL.. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.Clin Cancer Res.2002; 8: 3584–3591.
34.
MatsuyamaS., IwadateM., KondoM.. SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells.Cancer Res.2003; 63: 7791–7798.
35.
GrecoA., RoccatoE., MirandaC.. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement.Int J Cancer.2001; 92: 354–360.
36.
HotfilderM., LanversC., JürgensH.. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).Cancer Chemother Pharmacol.2002; 50: 167–169.
37.
StewartC.F., LeggasM., SchuetzJ.D.. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.Cancer Res.2004; 64: 7491–7499.
38.
KuenenB.C., TaberneroJ., BaselgaJ.. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.Clin Cancer Res.2003; 9: 1648–1655.
39.
AngelovL., SalhiaB., RoncariL.. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas.Cancer Res.1999; 59: 5536–5541.
40.
DalalS., BerryA.M., CullinaneC.J.. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family.Clin Cancer Res.2005; 11: 2364–2378.
41.
GingrichD.E., ReddyD.R., IqbalM.A.. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl) indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.J Med Chem.2003; 46: 5375–5388.
42.
ScotlandiK., ManaraM.C., NicolettiG.. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.Cancer Res.2005; 65: 3868–3876.
43.
ShorA.C., KeschmanE.A., LeeF.Y.. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival.Cancer Res.2007; 67: 2800–2808.
44.
BalasubramanianL., EvensA.M.. Targeting angiogenesis for the treatment of sarcoma.Curr Opin Oncol.2006; 18: 354–359.
45.
YeD., MaitraA., TimmonsC.F.. The epidermal growth factor receptor HER2 is not a major therapeutic target in Ewing sarcoma.J Pediatr Hematol Oncol.2003; 25: 459–466.
46.
GuanH., JiaS.F., ZhouZ.. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo.Clin Cancer Res.2005; 11: 2008–2017.
47.
D'AdamoD.R., AndersonS.E., AlbrittonK.. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.J Clin Oncol.2005; 23: 7135–7142.
48.
AziziA.A., HaberlerC., CzechT.. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma.Lancet Oncol.2006; 7: 521–523.
49.
BondM., BernsteinM.L., PappoA.. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.Pediatr Blood Cancer.2007 Jan 29. Epub ahead of print.
50.
SatoO., WadaT., KawaiA.. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases.Cancer.2005; 103: 1881–1890.
51.
DawN.C., FurmanW.L., StewartC.F.. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.J Clin Oncol.2005; 23: 6172–6180.
52.
ScotlandiK., ManaraM.C., HattingerC.M.. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.Eur J Cancer.2005; 41: 1349–1361.
53.
AkatsukaT., WadaT., KokaiY.. ErbB2 expression is correlated with increased survival of patients with osteosarcoma.Cancer2002; 94: 1397–1404.
54.
HughesD.P., ThomasD.G., GiordanoT.J.. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma.Cancer Res.2004; 64: 2047–2053.
55.
ThomasD.G., GiordanoT.J., SandersD.. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.Cancer.2005; 103: 830–838.
56.
AhlénJ., WejdeJ., BrosjöO.,. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma.Clin Cancer Res.2005; 11: 206–216.
57.
WilhelmS.M., CarterC., TangL.. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res.2004; 64: 7099–7109.
58.
ChangY.S., AdnaneJ., TrailP.A.. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.Cancer Chemother Pharmacol.2007; 59: 561–574. Epub 2006 Dec 8.
59.
Rodriguez-VicianaP., TetsuO., OdaK.. Cancer targets in the Ras pathway.Cold Spring Harb Symp Quant Biol.2005; 70: 461–467.
60.
AdnaneL., TrailP.A., TaylorI.. Sorafenib (BAY 43-9006, Nex-avar®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.Methods Enzymol.2005; 407: 597–612.
61.
GuidaT., AnagantiS., ProviteraL.. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.Clin Cancer Res.2007; 13: 3363–3369.
62.
D'AdamoD.R., KeohanM., SchuetzeS.. Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060).J Clin Oncol.2007; 25 (18S June 20 suppl): 10001. Abstract.
